+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Parasitic Diseases Therapeutics Market 2019-2023 - Product Image

Global Parasitic Diseases Therapeutics Market 2019-2023

  • ID: 4791009
  • Report
  • June 2019
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanaria Inc.
  • MORE
Global Parasitic Diseases Therapeutics Market: About this market

Parasitic diseases include amebiasis, trichomoniasis, trypanosomiasis, giardiasis, African sleeping sickness, leishmaniasis, and malaria. The parasitic diseases therapeutics market analysis considers sales of antiprotozoal therapeutics, anthelminthic therapeutics, and Scabicides and pediculicides therapeutics. Our analysis also considers the sales of parasitic diseases therapeutics in Asia, Europe, North America, and ROW. In 2018, the antiprotozoal therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high incidence of amebiasis in developing countries and industrialized countries will play a significant role in the antiprotozoal therapeutics segment to maintain its market position. Also, our global parasitic diseases therapeutics market report looks at factors such as the high prevalence of parasitic infections, approval of therapeutics to treat parasitic diseases, increased funding for R&D. However, challenges associated with antiparasitic drug discovery and diagnosing of disease, increasing drug resistance, and lack of effective therapies and side-effects of drugs may hamper the growth of the parasitic diseases therapeutics industry over the forecast period.

Global Parasitic Diseases Therapeutics Market: Overview

Rising prevalence of parasitic infections

There is an increase in the number of cases of people infected by whipworms and hookworms. Also, infections caused by ectoparasites, helminths, and protozoa is increasing. The incidence of schistosomiasis is also growing on a global level. This will drive the need for parasitic disease therapeutics and lead to the expansion of the global parasitic diseases therapeutics market at a CAGR of about 5% during the forecast period.

Increasing adoption of prophylactic treatment

Researchers around the world are increasingly focusing on the development of vaccines due to the high prevalence of malaria. Diseases such as visceral leishmaniasis and cutaneous leishmaniasis can be prevented with the help of prophylactic vaccines. The development and consumption of such vaccines help in controlling parasitic diseases. This development is expected to have a positive impact on the overall market growth.

\
Competitive Landscape

With the presence of several major players, the global parasitic diseases therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parasitic diseases therapeutics manufacturers, that include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., and Sanaria Inc.

Also, the parasitic diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanaria Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Antiprotozoal therapeutics - Market size and forecast 2018-2023
  • Anthelminthic therapeutics - Market size and forecast 2018-2023
  • Scabicides and pediculicides therapeutics - Market size and forecast
  • 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Favorable drug pipeline
  • Increasing initiatives to eliminate parasitic diseases
  • Increasing adoption of prophylactic treatment
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanaria Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Drugs used to treat various parasitic diseases
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antiprotozoal therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antiprotozoal therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Anthelminthic therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Anthelminthic therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Scabicides and pediculicides therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Scabicides and pediculicides therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 32: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Drug candidates under development
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bayer AG - Vendor overview
Exhibit 48: Bayer AG - Business segments
Exhibit 49: Bayer AG - Organizational developments
Exhibit 50: Bayer AG - Geographic focus
Exhibit 51: Bayer AG - Segment focus
Exhibit 52: Bayer AG - Key offerings
Exhibit 53: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 54: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 55: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 56: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 57: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 58: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 59: GlaxoSmithKline Plc - Vendor overview
Exhibit 60: GlaxoSmithKline Plc - Business segments
Exhibit 61: GlaxoSmithKline Plc - Organizational developments
Exhibit 62: GlaxoSmithKline Plc - Geographic focus
Exhibit 63: GlaxoSmithKline Plc - Segment focus
Exhibit 64: GlaxoSmithKline Plc - Key offerings
Exhibit 65: Pfizer Inc. - Vendor overview
Exhibit 66: Pfizer Inc. - Business segments
Exhibit 67: Pfizer Inc. - Organizational developments
Exhibit 68: Pfizer Inc. - Geographic focus
Exhibit 69: Pfizer Inc. - Segment focus
Exhibit 70: Pfizer Inc. - Key offerings
Exhibit 71: Sanaria Inc. - Vendor overview
Exhibit 72: Sanaria Inc. - Key offerings
Exhibit 73: Validation techniques employed for market sizing
Exhibit 74: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanaria Inc.
  • MORE
The following companies are recognised as the key players in the global parasitic diseases therapeutics market: Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., and Sanaria Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing adoption of prophylactic treatment.”

According to the report, one of the major drivers for this market is the rising prevalence of parasitic infections.

Further, the report states that one of the major factors hindering the growth of this market is the increasing drug resistance.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanaria Inc.
Note: Product cover images may vary from those shown
Adroll
adroll